Iwata Chizaki Construction Co., Ltd. Implements 'Misignal Scan' Urine Cancer Risk Test as Employee Benefit
Key facts
- Iwata Chizaki Construction Co., Ltd. Implements 'Misignal Scan' Urine Cancer Risk Test as Employee Benefit
- Iwata Chizaki Construction has implemented Craif Inc.'s 'Misignal Scan' urine cancer risk test as an employee benefit. The initiative aims to support employee health management, early disease detection, and prevention.
- Source: PR Times
- Date: May 29, 2026
Direct answer
Iwata Chizaki Construction has implemented Craif Inc.'s 'Misignal Scan' urine cancer risk test as an employee benefit. The initiative aims to support employee health management, early disease detection, and prevention.
- Citation
- Iwata Chizaki Construction Co., Ltd. Implements 'Misignal Scan' Urine Cancer Risk Test as Employee Benefit (May 29, 2026), PR Times
- Source
- PR Times
- Date
- May 29, 2026
Iwata Chizaki Construction has implemented Craif Inc.'s 'Misignal Scan' urine cancer risk test as an employee benefit. The initiative aims to support employee health management, early disease detection, and prevention.
📋 Article Processing Timeline
- 📰 Published: May 29, 2026 at 19:00
- 🔍 Collected: May 30, 2026 at 22:27 (27h 27m after Published)
- 🤖 AI Analyzed: May 30, 2026 at 22:30 (2 min after Collected)
Craif Inc. announced that Iwata Chizaki Construction Co., Ltd. has adopted the 'Misignal Scan' urine cancer risk test as part of its employee benefits program.
■ Purpose of Implementation
Iwata Chizaki Construction believes that strengthening health promotion efforts is essential to create an environment where each employee can maintain their health and work enthusiastically for the future. Given this background, the company has introduced the 'Misignal Scan' as part of its health-related benefits starting this fiscal year. The company evaluated the product for its ease of use—requiring only a urine sample—and its ability to detect risks for up to 10 types of cancer, even at Stage 1. Through this initiative, the company aims to raise employees' health awareness, facilitate early disease detection, and further advance its 'Health and Productivity Management.'
■ About 'Misignal Scan'
Misignal Scan is a cancer risk test that extracts and analyzes microRNA from urine to determine the risk of up to 10 types of cancer from Stage 1 with high precision. As a urine test, it imposes no physical burden and can be performed from home via mail, minimizing effort. It has been adopted by over 2,000 medical institutions nationwide, and results, such as early detection of lung cancer, have been reported in Hokkaido.
[10 Cancer Types Detected]
Lung, Colorectal, Pancreatic, Gastric, Esophageal, Kidney, Bladder, Prostate (men only), Breast (women only), Ovarian (women only).
* The Misignal series is not a medical device. It is not a substitute for a medical diagnosis, and a low-risk result does not guarantee the absence of cancer.
■ About Craif
Craif Inc. is a Bio-AI startup focused on early cancer detection. By combining its proprietary analytical technology platform, 'NANO IP®,' with AI, the company is developing innovative tests to enable ultra-early cancer detection. Its vision is to realize a society where people can live out their full natural lifespans.
■ Purpose of Implementation
Iwata Chizaki Construction believes that strengthening health promotion efforts is essential to create an environment where each employee can maintain their health and work enthusiastically for the future. Given this background, the company has introduced the 'Misignal Scan' as part of its health-related benefits starting this fiscal year. The company evaluated the product for its ease of use—requiring only a urine sample—and its ability to detect risks for up to 10 types of cancer, even at Stage 1. Through this initiative, the company aims to raise employees' health awareness, facilitate early disease detection, and further advance its 'Health and Productivity Management.'
■ About 'Misignal Scan'
Misignal Scan is a cancer risk test that extracts and analyzes microRNA from urine to determine the risk of up to 10 types of cancer from Stage 1 with high precision. As a urine test, it imposes no physical burden and can be performed from home via mail, minimizing effort. It has been adopted by over 2,000 medical institutions nationwide, and results, such as early detection of lung cancer, have been reported in Hokkaido.
[10 Cancer Types Detected]
Lung, Colorectal, Pancreatic, Gastric, Esophageal, Kidney, Bladder, Prostate (men only), Breast (women only), Ovarian (women only).
* The Misignal series is not a medical device. It is not a substitute for a medical diagnosis, and a low-risk result does not guarantee the absence of cancer.
■ About Craif
Craif Inc. is a Bio-AI startup focused on early cancer detection. By combining its proprietary analytical technology platform, 'NANO IP®,' with AI, the company is developing innovative tests to enable ultra-early cancer detection. Its vision is to realize a society where people can live out their full natural lifespans.
FAQ
What specific cancer risk test did Iwata Chizaki Construction Co., Ltd. introduce for employees in 2024?
Iwata Chizaki Construction introduced Craif Inc.'s 'Misignal Scan' urine cancer risk test for employees in 2024.
Which company provides the 'Misignal Scan' test now offered by Iwata Chizaki Construction?
Craif Inc. provides the 'Misignal Scan' urine cancer risk test now offered by Iwata Chizaki Construction.
What is the full name of the construction firm adopting the Misignal Scan benefit in 2024?
The full name is Iwata Chizaki Construction Co., Ltd., which adopted Misignal Scan in 2024.
How does Iwata Chizaki Construction support employee health with Craif's product in 2024?
Iwata Chizaki Construction supports employee health by offering Craif's Misignal Scan for early cancer detection in 2024.
What type of medical test is the Misignal Scan provided by Craif Inc. to employees?
The Misignal Scan provided by Craif Inc. is a urine-based cancer risk assessment test.